JP2021519599A - 抗原性ospaポリペプチド - Google Patents
抗原性ospaポリペプチド Download PDFInfo
- Publication number
- JP2021519599A JP2021519599A JP2020554527A JP2020554527A JP2021519599A JP 2021519599 A JP2021519599 A JP 2021519599A JP 2020554527 A JP2020554527 A JP 2020554527A JP 2020554527 A JP2020554527 A JP 2020554527A JP 2021519599 A JP2021519599 A JP 2021519599A
- Authority
- JP
- Japan
- Prior art keywords
- ospa
- ferritin
- polypeptide
- antigenic
- serotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01078—6,7-Dimethyl-8-ribityllumazine synthase (2.5.1.78)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002941A JP2024038345A (ja) | 2018-04-03 | 2024-01-12 | 抗原性ospaポリペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862652210P | 2018-04-03 | 2018-04-03 | |
| US62/652,210 | 2018-04-03 | ||
| PCT/US2019/025367 WO2019195276A1 (en) | 2018-04-03 | 2019-04-02 | Antigenic ospa polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002941A Division JP2024038345A (ja) | 2018-04-03 | 2024-01-12 | 抗原性ospaポリペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519599A true JP2021519599A (ja) | 2021-08-12 |
| JP2021519599A5 JP2021519599A5 (cg-RX-API-DMAC7.html) | 2022-04-07 |
Family
ID=66397424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554527A Pending JP2021519599A (ja) | 2018-04-03 | 2019-04-02 | 抗原性ospaポリペプチド |
| JP2024002941A Pending JP2024038345A (ja) | 2018-04-03 | 2024-01-12 | 抗原性ospaポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002941A Pending JP2024038345A (ja) | 2018-04-03 | 2024-01-12 | 抗原性ospaポリペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11993636B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773697A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021519599A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260077937A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112584858A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3095174A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019195276A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3534941A4 (en) * | 2016-11-07 | 2020-07-08 | The Wistar Institute Of Anatomy And Biology | CONSTRUCTIONS OF ANTI-DNA ANTIBODIES FOR USE AGAINST LYME DISEASE |
| JP7614841B2 (ja) | 2018-04-03 | 2025-01-16 | サノフイ | 抗原性呼吸器合胞体ウイルスポリペプチド |
| CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
| EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
| CN111217919B (zh) * | 2020-03-04 | 2020-12-01 | 中山大学 | 一种基于火球菌铁蛋白的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
| CN111217918B (zh) * | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
| WO2023044016A2 (en) * | 2021-09-17 | 2023-03-23 | Cspc Dophen Corporation | Antibody immune-stimulant conjugates and use thereof |
| CA3242439A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
| WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
| CN114736293B (zh) * | 2022-06-14 | 2022-09-02 | 中国农业科学院生物技术研究所 | SARS-CoV-2中和性纳米抗体、自组装铁蛋白融合纳米抗体及制备方法和应用 |
| JP2026525284A (ja) * | 2023-07-10 | 2026-07-29 | ダイナヴァックス テクノロジーズ コーポレイション | アジュバントおよびborrelia細胞表層タンパク質a抗原を含むライム病ワクチン |
| EP4743110A1 (en) * | 2023-07-10 | 2026-05-20 | Dynavax Technologies Corporation | Lyme disease vaccines containing an adjuvant and Borrelia outer surface protein A and C antigens |
| WO2026132296A2 (en) * | 2024-12-20 | 2026-06-25 | Bavarian Nordic A/S | Multimeric lyme disease antigen particles |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013529078A (ja) * | 2010-05-14 | 2013-07-18 | バクスター・インターナショナル・インコーポレイテッド | Ospaキメラおよびそのワクチンでの使用法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO2001075436A1 (en) | 2000-04-03 | 2001-10-11 | Board Of Trustees Of The Leland Stanford Junior University | A method for protein structure alignment |
| EP1311540B1 (en) * | 2000-08-18 | 2007-12-19 | Research Foundation Of State University Of New York | Altered ospa of borrelia burgdorferi |
| US7097841B2 (en) * | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| US7774185B2 (en) | 2004-09-14 | 2010-08-10 | International Business Machines Corporation | Protein structure alignment using cellular automata |
| US20100285051A1 (en) | 2007-12-21 | 2010-11-11 | Dominique Ingrid Lemoine | Vaccine |
| US20110117131A1 (en) * | 2008-04-09 | 2011-05-19 | Ning Huang | Production of OspA for Lyme Disease Control |
| CZ301541B6 (cs) * | 2008-06-25 | 2010-04-07 | Biologické centrum AV CR, v.v.i., Parazitologický ústav | Feritin 2 pro imunizaci organismu proti klíštatum |
| US20140186371A1 (en) | 2011-04-07 | 2014-07-03 | Guriqbal S. Basi | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition |
| JP5795184B2 (ja) | 2011-04-22 | 2015-10-14 | 国立大学法人 奈良先端科学技術大学院大学 | 被検物質の電気化学的検出方法 |
| EP2515112B1 (en) | 2011-04-22 | 2015-08-12 | Sysmex Corporation | Method for electrochemically detecting analyte |
| EP2877205A4 (en) | 2012-07-26 | 2016-04-06 | Jackson H M Found Military Med | VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY |
| CZ2014320A3 (cs) * | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| US10363301B2 (en) * | 2014-05-27 | 2019-07-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Stabilized influenza hemagglutinin stem region trimers and uses thereof |
| US9703095B2 (en) | 2015-01-05 | 2017-07-11 | Edward Pakhchyan | Light modulator for MEMS display |
| US10301377B2 (en) * | 2015-02-24 | 2019-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use |
| MX2018006785A (es) | 2015-12-04 | 2018-11-09 | Dana Farber Cancer Inst Inc | Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer. |
| KR102724939B1 (ko) | 2016-06-17 | 2024-11-01 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형 |
| EP3612562A2 (en) | 2017-04-19 | 2020-02-26 | Institute for Research in Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
| MA50813A (fr) | 2017-11-21 | 2020-09-30 | Modernatx Inc | Vaccins contre le virus d'epstein-barr |
-
2019
- 2019-04-02 CN CN201980035045.3A patent/CN112584858A/zh active Pending
- 2019-04-02 KR KR1020267014720A patent/KR20260077937A/ko active Pending
- 2019-04-02 EP EP19721893.6A patent/EP3773697A1/en active Pending
- 2019-04-02 KR KR1020207031415A patent/KR20210018205A/ko not_active Ceased
- 2019-04-02 WO PCT/US2019/025367 patent/WO2019195276A1/en not_active Ceased
- 2019-04-02 CA CA3095174A patent/CA3095174A1/en active Pending
- 2019-04-02 JP JP2020554527A patent/JP2021519599A/ja active Pending
-
2020
- 2020-10-01 US US17/061,155 patent/US11993636B2/en active Active
-
2024
- 2024-01-12 JP JP2024002941A patent/JP2024038345A/ja active Pending
- 2024-04-19 US US18/640,574 patent/US20240417432A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013529078A (ja) * | 2010-05-14 | 2013-07-18 | バクスター・インターナショナル・インコーポレイテッド | Ospaキメラおよびそのワクチンでの使用法 |
Non-Patent Citations (1)
| Title |
|---|
| COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2016, VOL.14, PP.58-68, JPN6023009411, ISSN: 0005149801 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240417432A1 (en) | 2024-12-19 |
| US11993636B2 (en) | 2024-05-28 |
| RU2020135567A (ru) | 2022-05-06 |
| KR20260077937A (ko) | 2026-05-28 |
| CN112584858A (zh) | 2021-03-30 |
| WO2019195276A1 (en) | 2019-10-10 |
| EP3773697A1 (en) | 2021-02-17 |
| JP2024038345A (ja) | 2024-03-19 |
| CA3095174A1 (en) | 2019-10-10 |
| US20210017238A1 (en) | 2021-01-21 |
| KR20210018205A (ko) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993636B2 (en) | Antigenic OspA polypeptides | |
| JP7719134B2 (ja) | 抗原性エプスタインバーウイルスポリペプチド | |
| US20240216497A1 (en) | Ferritin Proteins | |
| JP7536737B2 (ja) | Hpv及びhpv関連疾患に対する新規のワクチン | |
| JP7614841B2 (ja) | 抗原性呼吸器合胞体ウイルスポリペプチド | |
| JP2024041980A (ja) | 抗原性インフルエンザ-フェリチンポリペプチド | |
| EP4415753A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
| RU2816208C2 (ru) | АНТИГЕННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ ПОСЛЕДОВАТЕЛЬНОСТИ OspA | |
| RU2807992C2 (ru) | Антигенные полипептиды на основе последовательности респираторно-синцитиального вируса | |
| US20250242008A1 (en) | Pfcsp-based immunogens and related composition and methods | |
| TW202600163A (zh) | 經修飾的CMV類病毒粒子及IL-1β突變蛋白抗原之獸醫組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210525 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220330 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230620 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240112 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240202 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240517 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260721 |